Objective: To measure the levels of KLK6 and CA125 tumor marker and compare them as a predictor of epithelial type ovarian malignancy. KLK6 and CA125 were taken from blood serum of 60 ovarian tumor patients who met the inclusion criteria in consecutive sampling. CA125 quantitative examination and KLK6 titer were performed by ELISA. Surgical tissue from Dr. Soetomo Hospital, Surabaya was examined histopathologically at the Anatomical : This study is a diagnostic test using a cross-sectional design with a total sample of 60 ovarian tumor patients from obstetrics and gynecology outpatient clinic, . CA125 was examined by ELISA, while KLK6 was examined using an ELISA reagent kit from Enzo Life Sciences Inc., USA. Results: This study examined a total sample of 60 patients, 30 patients (50%) with benign ovarian tumors, 26 patients (43.33%) with stage I ovarian cancer and 4 patients (6.66%) with stage II ovarian cancer. The best cut off for KLK6 is 3.14ng/mL and the standard CA125 cut-off is 35U/mL. The sensitivity and specifi city of Ca125 are 70.00; 33.33, the sensitivity and specifi city of KLK6 are 50.00; 100.00, PPV and NPV of Ca125 are 51.22; 52.63, PPV and NPV of KLK6 are 100.00; 66.67. Conclusion: KLK6 showed high specifi city for the diagnosis of ovarian cancer. This can improve the diagnostic accuracy of Ca125 which has high sensitivity but low specifi city. A combined panel of Ca125 and KLK6 showed high diagnostic effi ciency for early-stage ovarian cancer.
and control the invasive behavior of epithelial type ovarian cancer in in vivo and in vitro metastases 6 .
Such evidences clearly connect kallikrein and cancer development so that it can be applied as a new biomarker for the diagnosis and management of epithelial type ovarian cancer 7 . Each biomarker and panel from kallikrein family can predict response to chemotherapy, overall survival, short term survival (1 year survival rate), survival (tumor free progression) of ovarian cancer patients treated with chemotherapy 8 .
With these various potentials, it is expected that KLK6 can match the sensitivity and specifi city of Ca125 which has been the gold standard of epithelial type ovarian cancer malignancy parameter. Moreover, Ca125 still has weaknesses, such as it can be applied to recurrent ovarian cancer, cancer persistency even though normal Ca125, and will not necessarily improve patient survival 9 . Th us, if KLK6 has very good sensitivity and specifi city, and cost-eff ective, it can be used as a parameter of malignancy. Moreover, KLK6 also has the potential as the target of epithelial ovarian cancer therapy 10 . Th erefore, this study was conducted with the aim of testing the accuracy, sensitivity, and specifi city of kallikrein-6 (KLK6) by comparing it with Ca125 at Dr. Soetomo Hospital, Surabaya. By knowing those things, hopefully KLK6 can be used as an accurate biomarker for epithelial type ovarian cancer which exceed or at least match with Ca125. Th e combination of both therapies will provide more benefi ts, especially for early detection of epithelial type ovarian cancer so that it can improve the patient's survival time and quality of life. 
MATERIALS AND METHODS

INTRODUCTION
Despite advances in therapy, ovarian cancer remains the most deadly gynecological cancers. Less than 30% of women with advanced stages survive in the long term. When diagnosed in stage I, up to 90% of patients can be cured by conventional surgery and chemotherapy. At present, only 25% of ovarian cancers are detected in stage I partly because there are no specifi c symptoms and less eff ective screening strategies.
Given the prevalence of ovarian cancer and the importance of early detection to get a good prognosis, screening for early detection must have high sensitivity at an early stage (>75%), and very high specifi city (99.6%) to achieve a positive predictive value >10% 1 . Screening which is commonly used now, Ca125 and pelvic ultrasonography, has limited effi cacy. In that case, one biomarker as parameters for early detection, screening and knowing disease progression is not enough and has to be more specifi c 2 .
Th e prognosis of cancer is determined by the ability to invade and metastasize. Metastasis is associated with invasive behavior of tumor cells in which cell membrane proteins, receptors, and extracellular matrix proteins play an important role. An important component in the protein regulation is proteases, an enzyme which plays a role in protein breakdown and catalyzes hydrolysis reactions. Hydrolysis reaction is a reaction involving water elements in specifi c substrate bonds, catalyzing the degradation of the interstitial matrix and basement membrane, allowing cancer cells to invade locally and metastasize to distant places. If protease is involved in the spread of cancer, it will have the potential to become new prognostic marker in cancer 3 .
In human body, protease that is widely expressed in ovarian cancer cells that play a role in cancer progression and metastases is kallikrein (KLK) 4 . It is known that the family of kallikrein gene in human tissue contains at least 15 genes. All genes have important similarity, which are mapping at the same chromosome locus (19q13.4), good signifi cant homology in both nucleotides and proteins, and the same genome arrangement. All genes encode a putative serine protease. It is known that some of the kalikrein genes are related to malignancy 5 . Kalikrein is expressed in many tissues, including tissues that produce steroid hormones or tissue-dependent hormones such as prostate, breast, ovary, and testicles. Most of kallikreins are regulated by steroid hormones in cancer cells 5 . Kallikrein is expected to act as a biomarker, indicator of disease progression, to see diff erences in serum KLK6 level between patients with benign ovary tumors and early stage ovarian cancer (stage I-II); the diff erence in tumor marker sensitivity and specifi city; and the correlation between CA125 and KLK6. SPSS software was used to simplify the statistical analysis.
Th e inclusion criteria were patients who were diagnosed with ovarian tumors and had undergone surgery at RSUD Dr. Soetomo, had never been diagnosed with malignancy in the fi eld of gynecology, and were willing to be the subject.
Exclusion criteria were non-epithelial ovarian cancer patients, stage III epithelial type ovarian cancer patients with or without ascites, and patients refusing to participate as the subject.
Predictors in this study were seen based on comparison of sensitivity, specifi city, Positive Predictive Value, and Negative Predictive Value between KLK6 and CA125. Th e result of serum CA125 levels with an immune assay examination above 35 U/mL indicates a suspicion of malignancy. Th e titer result of serum KLK6 level with an immune assay examination above or equal to 3.14 ng / mL indicates suspicion of malignancy. CA125 sensitivity is the number of ovarian cancer patients with serum CA125 level above 35 Ul/mL divided by the total number of ovarian cancer patients multiplied by 100%. CAl25 specifi city is the number of benign ovarian tumor patients with serum CA125 levels below 35 U/mL divided by the total number of patients with benign ovarian tumors multiplied by 100%. CA125 Positive Predictive Value is the number of ovarian cancer patients with serum CA125 levels above 35 U/mL divided by the total number of patients with serum CA125 levels above 35 U/mL multiplied by 100%. CA125 Negative Predictive Value is the number of benign ovarian tumor patients with serum CA125 levels below 35 U/mL divided by the total number of patients with serum CA125 levels below 35 U/mL multiplied by 100%. Th e sensitivity of KLK6 is the number of ovarian cancer patients with titer serum KLK6 levels above or equal to 3.14 ng/mL divided by the total number of epithelial cancer patients multiplied by 100%. Th e specifi city of KLK6 serum is the number of benign ovarian tumor patients with titer serum KLK6 levels below 3.14 ng/mL divided by the total number of patients with benign ovarian tumors multiplied by 100%. KLK6 Positive Predictive Value is the number of ovarian cancer patients with titer serum KLK6 level above or equal to 3.14 ng/mL divided by the total number of patients with titer serum KLK6 levels above or equal to 3.14 ng/mL multiplied 100%. KLK6 Negative Predictive Value is the number of patients with benign ovarian tumors with titer serum KLK6 levels below 3.14 ng/mL divided by the total number of patients with titer serum KLK6 levels below 3.14 ng/mL multiplied by 100%.
Statistical analysis was conducted using MED-CALC software. Statistical calculations used a signifi cance level of p = 0.05 (5%). It would be signifi cant if p<0.05, on the contrary, if p>0.05, it was interpreted as insignifi cant. Th e researcher used the Receiver Operating Characteristic (ROC) curve to measure the performance of tumor markers. Th e area under the ROC curve of CA-125 (0.447) was lower than KLK6 (0.737). AUC approaching 1.0 indicates that the test has almost perfect discrimination, while AUC near 0.5 indicates poor discrimination.
RESULTS
Th e results obtained a total sample of 60 patients, 30 patients (50%) with benign ovarian tumors, 26 patients (43.33%) with stage I ovarian cancer and 4 patients (6.66%) with stage II ovarian cancer.
Th e mean age of the healthy patient was 45.1 years, stage I ovarian cancer group was 49.3 years, stage III ovarian cancer group was 49.7 years. Th e statistical analysis of the three groups showed a normally distributed data and the comparison was signifi cant (p = 0.027). Table 5 .1 showed the mean age in the cancer patients group was 46.3 years and the benign tumor group was 49.3 years. Based on the statistical analysis using T-test 2 free samples, the data was normally distributed but was not signifi cant (p = 0.907).
Th e mean KLK6 in the healthy patient was 1.62 ng / mL, stage I ovarian cancer group was 12.05ng / on while compared to the CA-125 (33.33%) as a standard. Figure 1 showed the KLK6 accuracy in determining ovarian cancer was 0.737. Figure 2 showed that the accuracy of CA125 in determining ovarian cancer was 0.447.
DISCUSSION
Ovarian cancer is the biggest cause of cancer-related deaths in women in Western Europe and the United States, and has the highest mortality rate of all gynecological malignancies. Th e mean age of early ovarian cancer patients is around 37.2 -55.7 years 10 . In this study, the mean age was 46.3. Th e pre-cancer to insitu cancer stage age was 37.2 -46.3 years (Table 1) . Another study from Egypt by Sherbini et al. reported that the mean age of advanced ovarian cancer incidence was 59.8 year, so it can be concluded that at the age of 45 years or at the pre menopause stage, tumor marker mL, and stage III ovarian cancer group was 110.79ng / mL. Based on the statistical analysis comparisons of the three groups, data was not normally distributed but signifi cant (p = 0.001).
Th e mean CA-125 in the healthy patient was 15.37 U / mL, stage I ovarian cancer group was, 125.41 U / mL, and stage III ovarian cancer group was 1021.80 U / mL with statistical analysis comparison of the three groups found that the data were not normally distributed and the results were signifi cant (p = 0.001). Table 5 .2. showed various types of cut-off s of KLK6, it turned out that the results were the same as other studies, which was able to predict ovarian malignancy at a cut off of 3.14 ng / mL (p<0.05). Table 3 below showed the examination of single CA-125 tumor markers had the highest sensitivity (70.00%) compared to KLK6 with a cut off of 3.14 ng/ mL (50.00%). Th e highest specifi city was possessed by KLK6 with a cut off of 3.14 ng/mL (100%) both used as a single tumor marker examination or in combinati- As a traditional biomarker of ovarian cancer, CA125 has been used for 20 years. An insignifi cant increase in CA-125 to detect early-stage ovarian cancer is associated with a high sensitivity of CA125 which also increases in endometriosis and chronic infection. CA125 also has low specifi city; for example, an increasing is found in a variety of benign gynecological diseases. Among studies that met the requirements, there were 3 original studies comparing the diagnostic effi ciency of KLK6 and CA125. Koh et al. found that sensitivity and specifi city of KLK6 were lower than CA125, but the combination of KLK6 and CA125 showed higher diagnostic effi ciency 12 . El Sherbini et al and Diamandis et al found that KLK6 serum may have an overall sensitivity that is much lower than CA125 serum. However, KLK6 serum can increase the sensitivity of CA125. In contrast, Table 5 .2 showed that a signifi cant increase in KLK6 (p = 0.002) was more specifi c for ovarian cancer than CA125 because it did not increase in the benign tumors. Th erefore, whether the diagnostic effi ciency of KLK6 is superior to CA125 remains to be clarifi ed. However, all of these studies clearly support that KLK6 can improve CA125 diagnostic effi ciency 11, 13 .
Previous studies found that KLK6 cut-off s were diff erent. .79 ng/mL. Finally, most of the researches agreed that the best cut off of KLK6 was 3.14 ng / mL [11] [12] [13] [14] [15] .
Our study showed various types of cut-off s from KLK6 that were similar to other studies, which proposed the best cut-off of 3.14 ng / mL (p<0.05) to predict ovarian malignancy. Sensitivity for detecting early stage ovarian cancer; KLK6, Ca125 (50.00% vs 70.00%), Specifi city for detecting early stage ovarian cancer; KLK6, Ca125 (100.0% vs 33.33%), Positive Predictive Value to detect early stage ovarian cancer; KLK6, Ca125 (100% vs 51.22%). KLK6 serum is a new biomarker for ovarian carcinoma. Th is biomarker is more specifi c for ovarian cancer than CA-125 because elevation is not seen in benign diseases. KLK6 diagnostic and ultrasound screening are needed for early detection of ovarian cancer 11 . Th ere is no clear noninvasive or biomarker test to diagnose ovarian cancer, and the majority of patients diagnosed at an advanced stage have Th e KLK6 serum is likely to originate from tumor cells because its level decreases signifi cantly in the postoperative stage. Th e study of Hoff man BR which examined the prognostic value of KLK6 on ovarian tumor extracts, found KLK6 over expression in tumor cells by immune histochemistry and subsequently proofed that KLK6 intratumor concentration was also a strong prognostic indicator. Serine proteases which do not belong to the kallikrein family also have signifi cance prognostic in ovarian cancers, including trypsin, prostacin, hepsin, and testisin. It has been known for years that many other proteolytic enzymes have prognostic value in various types of cancer. Th e biological mechanism for the involvement of proteolytic enzymes in the prognosis of cancer includes their ability to decrease the extracellular matrix, thereby facilitating invasion and metastasis. It seems that some family members of the human kallikrein gene are dysregulated in ovarian cancer. Th us, other members of this family will emerge as potential biomarkers of ovarian cancer. If these proteases are involved in the development of cancer, they may be suitable candidates as therapeutic targets. Th is possibility is worthy of further investigation 17 .
Yousef GM et al. showed an example of monitoring ovarian cancer patients with KLK6 serum. More detailed studies are needed to overcome the monitoring problem of patients whose tumors do not produce CA-125 but still issue KLK6. We also showed that KLK6 serum did not increase signifi cantly in breast, thyroid, testicular, gastrointestinal, prostate, and lung cancers. Th us, KLK6 serum seems to be a specifi c ovarian cancer biomarker 18 .
High specifi city in KLK6 humans shows that this is a new biomarker potential for ovarian cancer. Th is clearly can improve the diagnostic effi ciency of ovarian cancer and KLK6 can improve CA125 diagnostic accuracy. A combination of CA125 and KLK6 shows high diagnostic effi ciency (increasing diagnostic sensitivity) for ovarian cancer in all stages. Because of the limitations in this meta-analysis, additional research is needed to assess the accuracy of KLK6 diagnostics in the future 11, 14, 19 .
CONCLUSION
KLK6 is a new biomarker with high specifi city for the diagnosis of ovarian cancer. Th is can improve the diagnostic accuracy of Ca125 which has high sensitivity but low specifi city. A combined panel of Ca125 and KLK6 showed high diagnostic effi ciency for early-sta-sensitivity is lower than the diagnostic sensitivity of CA-125 in the early stage ovarian cancer group.
KLK6 serum is a new biomarker for ovarian carcinoma. Th is biomarker is more specifi c for ovarian cancer than CA-125 because elevation is not seen in benign diseases. Th e diagnostic sensitivity of KLK6 is lower than CA-125 in the early stage ovarian cancer group (Table 5 .4.). As discussed by Jacobs et al, the sensitivity and specifi city of CA125 and KLK6, and their combination still does not meet the criteria for using these markers in the population screening setting 16 .
Our data showed that none of these two markers would be satisfying for early ovarian cancer markers. However, the combination between CA125 and KLK6 seems to complement each other with better specificity and same sensitivity compared to CA125 alone. Possible implications of the diff erence in frequency distribution curves from two markers and the proportion of late stage cancer cases when choosing statistical inference tests to evaluate the diff erentiating ability of tumor markers.
Th e results of our meta-analysis used Kappa test and Mc Nemar test which aimed to see the suitability of the results between tumor markers and their clinical fi ndings, indicating that serum KLK6 levels could help predict the presence of ovarian cancer based on AUC (AUC = 0.737). Th ese data indicate that KLK6 is a useful diagnostic marker for ovarian cancer. Th e poor sensitivity of KLK6 clearly limits its benefi ts in the diagnosis of ovarian cancer. However, high specifi city also makes it a potential biomarker of ovarian cancer.
KLK6 also increases more frequently at an advanced stage and with a higher degree of disease. KLK6 is a strong prognostic indicator for the patient's condition. Patients with pre-operative KLK6 above 3.14 ng/mL had worse prognosis than patients with low pre-operative KLK6. CA-125 prognostic value disappeared in multivariate analysis, while KLK6 was an independent prognostic indicator, as shown in multivariate analysis.
We responded data from Diamandis et al about the response of chemotherapy and Kaplan-Meier curves as follows: (1) Almost all patients with high pre-operative KLK6 relapsed within 6 years, and most of them died;
(2) 81% patients who did not respond to chemotherapy had high preoperative KLK6. Th us, high pre-operative KLK6 identifi es patients who are refractory to chemotherapy, who will experience recurrence and death. Th ese patients must be good candidates for other clinical trials, not chemotherapy. More appropriate clinical studies are needed to deal those problems 13 . authors declare that all the procedures and experiments of this study respect the ethical standards in the Helsinki Declaration of 1975, as revised in 2008 (5) , as well as the national law. Informed consent was obtained from all the patients included in the study. ge ovarian cancer. Our study is still ha ving some limitations, additional research is needed to assess the accuracy of KKL6 diagnostic.
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